Trial reportBMC infectious diseases2026
Vonoprazan versus rabeprazole in dual therapy with amoxicillin for Helicobacter pylori eradication: a prospective, multicenter, open-label, randomized controlled trial.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth traditional proton pump inhibitors and the novel potassium-competitive acid blocker vonoprazan, when combined with high-dose amoxicillin in dual therapy, have shown promise for Helicobacter pylori (H. pylori) eradication. However, high-quality evidence directly comparing their efficacy and safety remains limited. This study aimed to compare the clinical efficacy and safety of rabeprazole-amoxicillin dual therapy versus vonoprazan-amoxicillin dual therapy for H. pylori eradication.
methodsFrom April 1, 2024, to February 28, 2025, 318 H. pylori-positive patients were enrolled and randomly assigned in a 1:1 ratio to two treatment groups: the Rabeprazole Group (rabeprazole 20 mg twice daily; amoxicillin 1000 mg three times daily) and the Vonoprazan Group (vonoprazan 20 mg twice daily; amoxicillin 1000 mg three times daily). Both groups received a 14-day treatment course. A 13C-urea breath test was performed at least four weeks after treatment completion. H. pylori eradication rates, incidence of adverse events during treatment, and medication adherence were compared between the groups.
resultsIn the intention-to-treat analysis, the eradication rates were 75.5% (95% CI: 68.8%-82.2%) in the Rabeprazole Group and 83.0% (95% CI: 77.2%-88.9%) in the Vonoprazan Group, with no statistically significant difference (P = 0.097). In the modified intention-to-treat analysis, the rates were 78.4% (95% CI: 71.9%-84.9%) and 88.6% (95% CI: 83.5%-93.7%), respectively, showing a significant difference (P = 0.018). In the per-protocol analysis, the rates were 79.7% (95% CI: 73.1%-86.3%) and 90.1% (95% CI: 85.1%-95.0%), respectively, also showing a significant difference (P = 0.015). The incidence of adverse events was low in both groups (10.5% vs. 12.8%, P = 0.533). Medication adherence did not differ significantly between the groups (P = 0.648). Manual labor occupation was identified as a risk factor for eradication failure (adjusted OR = 2.153, 95% CI: 1.067 to 4.346, P = 0.032).
conclusionVonoprazan-amoxicillin dual therapy achieves satisfactory outcomes for H. pylori eradication, with a significantly higher eradication rate than the traditional rabeprazole-amoxicillin dual regimen. As a novel acid suppressant, vonoprazan demonstrates significant clinical advantages and broad application potential in dual-therapy regimens for H. pylori eradication. CLINICAL
trial registrationhttps://www.medicalresearch.org.cn/ , identifier ChiCTR2400082319. Registered on March 5, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.